NCT02431559 2022-10-10Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian CancerLudwig Institute for Cancer ResearchPhase 1/2 Completed53 enrolled 22 charts
NCT01666444 2019-09-26VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerCelgenePhase 2 Completed297 enrolled 15 charts